SEC filings and other documents

Phase I trials for TriKE therapies show early promise, with key data readouts expected soon.

TriKE® nanobody platform advances NK cell therapies for cancer and autoimmune diseases.

Q2 2026 net loss narrowed to $4.5M as clinical programs advance and cash runway extends to Q4 2026.

Three TriKE® candidates in clinical trials; cash runway through Q4 2026; net loss increased.

NK cell engager platform shows strong clinical promise for cancer and autoimmune diseases.

TriKE® nanobody platform advances next-gen NK cell therapies for cancer and autoimmune disease.

Net loss increased to $28.4M in 2025, with cash runway projected through Q4 2026.

Q3 2025 net loss narrowed to $3.1M as clinical progress continues and cash funds operations into Q1 2026.

Trispecific nanobody platform shows potent NK cell activation and expansion into solid tumors.

Net loss narrowed and clinical pipeline advanced, with cash to fund operations into Q1 2026.

Q1 2025 net loss narrowed, new financing secured, and lead TriKE® candidate advanced to Phase 1.

TriKE platform delivers targeted NK cell therapies with clinical proof and expanding pipeline.

Net loss widened to $13.2M in 2024 as GT Biopharma advances its TriKE® pipeline amid funding risks.

TriKE® platform delivers targeted NK cell therapies with clinical validation and broad pipeline.

GT Biopharma's TriKE® pipeline progresses as cash reserves support operations into Q2 2025.

Q2 2024 net loss widened to $3.7M as GT Biopharma advances its TriKE pipeline and clinical programs.

Two TriKE® programs advanced, with $9.81 million in cash and investments supporting runway into 2025.

Lower expenses narrowed FY 2023 losses as two TriKE programs advanced toward 2024 milestones.